Last reviewed · How we verify
Extended-release lorazepam
Extended-release lorazepam is a benzodiazepine that enhances the inhibitory neurotransmitter GABA at the GABA-A receptor, producing anxiolytic, sedative, and anticonvulsant effects.
Extended-release lorazepam is a benzodiazepine that enhances the inhibitory neurotransmitter GABA at the GABA-A receptor, producing anxiolytic, sedative, and anticonvulsant effects. Used for Anxiety disorders, Insomnia, Seizure disorders.
At a glance
| Generic name | Extended-release lorazepam |
|---|---|
| Also known as | EDG004 |
| Sponsor | Edgemont Pharmaceuticals, LLC |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Lorazepam potentiates GABA-A receptor signaling in the central nervous system, increasing chloride ion influx and neuronal hyperpolarization. This results in reduced neuronal excitability and produces anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. The extended-release formulation is designed to provide sustained therapeutic levels with once-daily dosing, improving compliance compared to immediate-release formulations.
Approved indications
- Anxiety disorders
- Insomnia
- Seizure disorders
Common side effects
- Sedation / Drowsiness
- Dizziness
- Ataxia / Coordination impairment
- Dependence / Withdrawal risk
- Cognitive impairment
- Headache
Key clinical trials
- EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD) (PHASE3)
- A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise (PHASE4)
- IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended-release lorazepam CI brief — competitive landscape report
- Extended-release lorazepam updates RSS · CI watch RSS
- Edgemont Pharmaceuticals, LLC portfolio CI